Health and Healthcare

Tuesday's Top Biotech and Medical Stocks

From BioHealth Investor

Biotechnology

PIPEX PHARMACEUTICAL [PPXP.OB] +42.50%
BIONOVO INC [BNVI.OB] +15.87%
NEUROBIOLOGICAL TECH [NTII] +13.93%
REPROS THERAPEUTICS [RPRX] +10.24%
OBAGI MEDICAL [OMPI] +9.90%

Diagnostic Substances

LEXICON GENETICS I [LEXG] +8.50%
GENELABS TECH INC [GNLB] +6.21%
EZ EM INC [EZEM] +5.59%
SURMODICS INC [SRDX] +4.06%
OSTEOLOGIX INC [OLGX.OB] +4.00%

Drug Delivery

COLUMBIA LABS INC [CBRX] +4.57%
FLAMEL TECH SA ADR [FLML] +3.14%
DELCATH SYSTEMS INC [DCTH] +2.79%
EMISPHERE TECH [EMIS] +2.12%
K V PHARMA CL A [KV-A] +1.73%

Drug Manufacturers

ATHEROGENICS INC [AGIX] +13.77%
EXEGENICS INC [EXEG.OB] +9.38%
NITROMED, INC. [NTMD] +7.69%
ALTAIR NANOTECH INC [ALTI] +6.54%
REGENERX BIOPHARM IN [RGN] +6.19%

Medical Appliances & Equipment

THERAGENICS CORP [TGX] +27.17%
ALIGN TECHNOLOGY I [ALGN] +21.21%
REGENERATION TECH [RTIX] +7.88%
EDAP TMS SA ADR [EDAP] +7.88%
ZIMMER HOLDINGS INC [ZMH] +5.92%

Medical Instruments & Supplies

BIOFORCE NANOSCIENCE [BFNH.OB] +12.50%
HEMOSENSE INC. [HEM] +5.70%
UROPLASTY INC [UPI] +5.43%
KENSEY NASH CP [KNSY] +4.00%
VASCULAR SOLUTIONS [VASC] +3.97%

Medical Laboratories & Research

PREMD INC [PME] +4.79%
MEDTOX SCIENTFIC INC [MTOX] +4.00%
ERESEARCHTECHNOLOG [ERES] +1.91%
NATL DENTEX CP [NADX] +1.80%
OSI PHARMACEUTIC [OSIP] +1.55%

http://www.biohealthinvestor.com/

Smart Investors Are Quietly Loading Up on These “Dividend Legends”

If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.

Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.